Medicus Pharma LtdTSXV:MDCXView on NASDAQ
- LAST PRICE2.9000
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots2.8500/ 1
- Ask / Lots3.0600/ 2
- Open / Previous Close3.0000 / 2.9000
- Day Range
- 52 Week Range
- Volume1,000
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MDCX |
|---|---|---|
| 09:37 ET | 200 | 2.95 |
| 09:42 ET | 100 | 2.9 |
| 10:27 ET | 300 | 2.97 |
| 10:44 ET | 200 | 3.05 |
| 11:12 ET | 200 | 2.9 |
Today
Medicus Pharma Ltd. Appoints Faisal Mehmud, MD, MRCP as Chief Medical Officer, from 15 hours ago by Dow Jones
15 hours ago by Dow JonesMedicus Pharma Ltd. Appoints Faisal Mehmud, MD, MRCP as Chief Medical Officer, from 15 hours ago by Dow Jones
15 hours ago by Dow JonesPress Release: Medicus Pharma Ltd. Appoints Faisal Mehmud, MD, MRCP as Chief Medical Officer, from 15 hours ago by Dow Jones
15 hours ago by Dow Jones
Nov 15, 2024
Medicus Pharma Ltd. Announces Closing of US$4.0M Initial Public Offering in the United States, from 4:48PM ET on Friday Nov 15, 2024 by Dow Jones
4:48PM ET on Friday Nov 15, 2024 by Dow Jones
Nov 14, 2024
DJ Medicus Pharma Shares Fall After IPO, from 2:26PM ET on Thursday Nov 14, 2024 by Dow Jones
2:26PM ET on Thursday Nov 14, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Medicus Pharma Ltd | 31.5M | -0.8x | --- |
LSL Pharma Group Inc | 52.0M | -19.4x | --- |
BioNxt Solutions Inc | 26.6M | -3.9x | --- |
Pharmather Holdings Ltd | 19.0M | -9.0x | --- |
Devonian Health Group Inc | 19.3M | -6.0x | --- |
Kane Biotech Inc | 13.8M | -2.5x | --- |
Company Information
Medicus Pharma Ltd. is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutic assets. Its subsidiaries include SkinJect, Inc, and Medicus Pharma Inc. The Company’s wholly owned subsidiary, SkinJect, Inc (SkinJect), is focused on commercializing a novel, non-invasive treatment for basal cell skin cancer using a patented dissolvable microneedle patch to deliver chemotherapeutic agent to eradicate tumor cells. The Company’s wholly owned subsidiaries are focused on the development of a drug delivery system using a dissolvable microneedle array for the treatment of certain skin cancers. The Company investigates opportunities across all therapeutic areas where an unmet need exists for improved patient safety and efficacy. The Company is actively exploring expanding its drug development pipeline through qualified and accretive acquisitions and partnerships.
Contact Information
- Headquarters
- 100 King Street West, Suite 3400TORONTO, ON, Canada M5X 1A4
- Phone
- 905-681-1925
- Fax
- 905-681-1925
Executives
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $31.5M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 10.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-3.59 |
Book Value | $0.14 |
P/E Ratio | -0.8x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
